The role of the PI3K pathway in colorectal cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2015-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2014.12.006PMID 25591826
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

  2014cited by this paper
• First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

  2014cited by this paper
• 11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer

  2014cited by this paper
• Stage at diagnosis and colorectal cancer survival in six high-income countries: A population-based study of patients diagnosed during 2000–2007

  2013cited by this paper
• PTEN expression profiles in colorectal adenocarcinoma and its precancerous lesions.

  2013cited by this paper
• Everolimus in colorectal cancer

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.

  2013cited by this paper
• Development of PI3K inhibitors: lessons learned from early clinical trials

  2013cited by this paper
• Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma

  2013cited by this paper
• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

  2013cited by this paper
• Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

  2013cited by this paper
• Evaluating many treatments and biomarkers in oncology: a new design.

  2013cited by this paper
• Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.

  2013cited by this paper
• Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.

  2013cited by this paper
• Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer

  2013cited by this paper
• Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

  2012cited by this paper
• Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision.

  2012cited by this paper
• Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

  2012cited by this paper
• A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

  2012cited by this paper
• PI3K expression and PIK3CA mutations are related to colorectal cancer metastases.

  2012cited by this paper
• The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

  2012cited by this paper
• Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

  2012cited by this paper
• Abstract 2913: Identification of GSK2636771, a potent and selective, orally bioavailable inhibitor of phosphatidylinositol 3-kinase-beta (PI3Kα) for the treatment of PTEN deficient tumors

  2012cited by this paper
• Phase I study of mFOLFOX-6, bevacizumab, and mTOR inhibitor RAD001 as first-line treatment of metastatic colorectal cancer.

  2012cited by this paper
• Genomic complexity and AKT dependence in serous ovarian cancer.

  2012cited by this paper
• Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

  2012cited by this paper
• Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

  2012cited by this paper
• Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients withPIK3CAmutant advanced solid tumors: preliminary efficacy and safety in patients withPIK3CAmutant ER-positive (ER+) metastatic breast cancer (MBC)

  2012cited by this paper
• PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.

  2012cited by this paper
• First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

  2011cited by this paper
• mTOR inhibitor everolimus (Ev) and IGFR inhibitor OSI-906 (OSI) for the treatment of patients (pts) with refractory metastatic colorectal cancer (mCRC): A Sarah Cannon Research Institute phase I trial.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102-Final report.

  2011cited by this paper
• Cancer statistics, 2011

  2011cited by this paper
• A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.

  2011cited by this paper
• The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer

  2011cited by this paper
• Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

  2011cited by this paper
• Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up.

  2010cited by this paper
• PI3-kinase/Wnt association mediates COX-2/PGE2 pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac

  2010cited by this paper
• The emerging mechanisms of isoform-specific PI3K signalling

  2010cited by this paper
• The PI3K pathway as drug target in human cancer.

  2010cited by this paper
• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

  2010cited by this paper
• A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.

  2010cited by this paper
• PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.

  2009cited by this paper
• Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

  2009cited by this paper
• The Pharmacology of mTOR Inhibition

  2009cited by this paper
• Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC).

  2009cited by this paper
• Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).

  2009cited by this paper
• The antiproliferative cytostatic effects of a self-activating viridin prodrug

  2009cited by this paper
• PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.

  2009cited by this paper
• PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

  2009cited by this paper
• Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy

  2008cited by this paper
• Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcΔ716 mice

  2008cited by this paper
• BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis?

  2008cited by this paper
• Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence?

  2008cited by this paper
• The life of a cell: apoptosis regulation by the PI3K/PKB pathway.

  2008cited by this paper
• Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

  2008cited by this paper
• PTEN-deficient cancers depend on PIK3CB

  2008cited by this paper
• PI3K pathway alterations in cancer: variations on a theme

  2008cited by this paper
• The PTEN–PI3K pathway: of feedbacks and cross-talks

  2008cited by this paper
• PIK3CA mutation is predictive of poor survival in patients with colorectal cancer

  2007cited by this paper
• A phase II trial of irinotecan, 5-fluorouracil and leucovorin in patients with previously untreated advanced colorectal cancer (CRC)

  2007cited by this paper
• Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans.

  2007cited by this paper
• Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.

  2007cited by this paper
• Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase.

  2006cited by this paper
• Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

  2006cited by this paper
• Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase

  2006cited by this paper
• mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

  2006cited by this paper
• The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

  2006cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• Oncogenic mutations of PIK3CA in human cancers.

  2004cited by this paper
• Oncogenic Mutations of PIK3CA in Human Cancers

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis.

  2002cited by this paper
• The phosphoinositide 3-kinase pathway.

  2002cited by this paper
• Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer

  2001cited by this paper
• Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

  2001cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

  2000cited by this paper
• Expression of the Tyrosine Kinase Activity Growth Factor Receptors (EGFR, ERB B2, ERB B3) in Colorectal Adenocarcinomas and Adenomas

  2000cited by this paper
• Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification.

  1999cited by this paper
• Genetics of Cowden syndrome: through the looking glass of oncology.

  1998cited by this paper
• Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

  1997cited by this paper
• Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.

  1997cited by this paper
• A genetic model for colorectal tumorigenesis.

  1990cited by this paper
• Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation

  1985cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper

• “A Fine-Tuned Phosphatidylinositol Profile Contributes to Colonocyte Differentiation and Malignization: Evidence From Integrated Omics”

  2026cites this paper
• Targeting Colorectal Cancer Liver Metastasis Through Repurposing Metabolic and Immune Inhibitors : A Theoretical Study

  2025cites this paper
• Lipid metabolic reprogramming in colorectal cancer: Insights to mechanisms and therapeutics

  2025cites this paper
• Hesperetin as a potential therapeutic agent for colorectal cancer: Targeting PI3K/AKT and EMT in cell lines through network pharmacology-guided strategies

  2025cites this paper
• TIM-3/Galectin-9 Immune Axis in Colorectal Cancer in Relation to KRAS, NRAS, BRAF, PIK3CA, AKT1 Mutations, MSI Status, and the Cytokine Milieu

  2025cites this paper
• Regulatory roles of ncRNAs in gastric cancer progression: a comprehensive insight into key signaling pathways

  2025cites this paper
• Nanomedicine innovations in colon and rectal cancer: advances in targeted drug and gene delivery systems

  2025cites this paper
• Clinicopathological significance of common PIK3CA exon mutations in non-metastatic colorectal cancer.

  2025cites this paper
• Targeting PI3K in Cancer Treatment: A Comprehensive Review with Insights from Clinical Outcomes.

  2025cites this paper
• Emerging trends in gastrointestinal cancers: Targeting developmental pathways in carcinogenesis and tumor progression.

  2024cites this paper
• Exploring the Key Signaling Pathways and ncRNAs in Colorectal Cancer

  2024cites this paper
• Identification of expression profiles and prognostic value of RFCs in colorectal cancer

  2024cites this paper
• Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment

  2024cites this paper
• MDFI promotes the proliferation and tolerance to chemotherapy of colorectal cancer cells by binding ITGB4/LAMB3 to activate the AKT signaling pathway

  2024cites this paper
• Claudins and hepatocellular carcinoma.

  2024cites this paper
• New sights of immunometabolism and agent progress in colitis associated colorectal cancer

  2024cites this paper
• Erratum to Colon cancer-associated transcript-1 enhances glucose metabolism and colon cancer cell activity in a high-glucose environment in vitro and in vivo

  2024cites this paper
• Targeting NUCKS1 with a fragment of tRNAAsn(GUU) of Chinese yew for the treatment of colorectal cancer

  2024cites this paper
• The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies

  2024cites this paper
• Interconnection of CD133 Stem Cell Marker with Autophagy and Apoptosis in Colorectal Cancer

  2024cites this paper
• MYC upstream region orchestrates resistance to PI3K inhibitors in cancer cells through FOXO3a-mediated autophagic adaptation

  2024cites this paper
• The essential roles of lncRNAs/PI3K/AKT axis in gastrointestinal tumors

  2024cites this paper
• Predict the Drug–Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ‐B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling

  2024cites this paper
• Genetic Insights into Colorectal Cancer: Evaluating PI3K/AKT Signaling Pathway Genes Expression

  2024cites this paper
• Navigating Molecular Pathways: An Update on Drugs in Colorectal Cancer Treatment.

  2023cites this paper
• A Systems Biology Approach to Understand the Racial Disparities in Colorectal Cancer

  2023cites this paper
• Chemopreventive Effects of Polysaccharides and Flavonoids from Okra Flowers in Azomethane/Dextran Sulfate Sodium-Induced Murine Colitis-Associated Cancer

  2023cites this paper
• Oncogene SCARNA12 as a potential diagnostic biomarker for colorectal cancer

  2023cites this paper
• Roles of phosphatidylinositol-3-kinases signaling pathway in inflammation-related cancer: Impact of rs10889677 variant and buparlisib in colitis-associated cancer

  2023cites this paper
• Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy

  2023cites this paper
• Bioinformatics and Expression Analyses of miR-639, miR-641, miR-1915-3p and miR-3613-3p in Colorectal Cancer Pathogenesis

  2023cites this paper
• Systems crosstalk between antiviral response and cancerous pathways via extracellular vesicles in HIV-1-associated colorectal cancer

  2023cites this paper
• Ethyl Acetate Extract of Halymenia durvillei Induced Apoptosis, Autophagy, and Cell Cycle Arrest in Colorectal Cancer Cells

  2023cites this paper
• Neuroendocrine differentiation: a risk fellow in colorectal cancer

  2023cites this paper
• PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma

  2023cites this paper
• To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway.

  2023cites this paper
• Novel splice variants of LINC00963 suppress colorectal cancer cell proliferation via miR-10a/miR-143/miR-217/miR-512-mediated regulation of PI3K/AKT and Wnt/β-catenin signaling pathways.

  2023cites this paper
• Therapeutic Intervention of Signaling Pathways in Colorectal Cancer

  2022cites this paper
• EVADR ceRNA transcript variants upregulate WNT and PI3K signaling pathways in SW480 and HCT116 cells by sponging miR-7 and miR-29b

  2022cites this paper
• 13-Acetoxysarcocrassolide induces apoptosis in human hepatocellular carcinoma cells through mitochondrial dysfunction and suppression of the PI3K/AKT/mTOR/p70S6K signalling pathway

  2022cites this paper
• Does IFITM3 link inflammation to tumorigenesis?

  2022cites this paper
• Nanostructured Silicon Enabled HR-MS for the Label-Free Detection of Biomarkers in Colorectal Cancer Plasma Small Extracellular Vesicles

  2022cites this paper
• Curcumin-Coated Poly(lactic-co-glycolic acid) Nanoparticles Affect Colorectal Cancer Cells Growth by Regulating Notch Signaling Pathway

  2022cites this paper
• Identification of Novel miRNAs, Targeting Genes, Signaling Pathway, and the Small Molecule for Overcoming Oxaliplatin Resistance of Metastatic Colorectal Cancer

  2022cites this paper
• Network Pharmacology and Molecular Docking on the Molecular Mechanism of Jiawei-Huang Lian-Gan Jiang Decoction in the Treatment of Colorectal Adenomas

  2022cites this paper
• Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited

  2022cites this paper
• The NOTCH4-GATA4-IRG1 axis as a novel target in early-onset colorectal cancer.

  2022cites this paper
• Altered Expression of TRIM Proteins-Inimical Outcome and Inimitable Oncogenic Function in Breast Cancer with Diverse Carcinogenic Hallmarks.

  2022cites this paper
• Reciprocal regulation of Daxx and PIK3CA promotes colorectal cancer cell growth

  2022cites this paper
• Clinical Characteristics and Prognostic Values of PIK3CA Mutation in Colorectal Cancer Patients

  2022cites this paper
• Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells

  2022cites this paper
• Predictive “omic” biomarkers of drug response: Colorectal cancer as a model

  2022cites this paper
• Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma

  2021cites this paper
• Inhibition of nucleophosmin 1 suppresses colorectal cancer tumor growth of patient -derived xenografts via activation of p53 and inhibition of AKT

  2021cites this paper
• Hypoxia-induced Nur77 activates PI3K/Akt signaling via suppression of Dicer/let-7i-5p to induce epithelial-to-mesenchymal transition

  2021cites this paper
• Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review)

  2021cites this paper
• TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance

  2021cites this paper
• Genetic regressive trajectories in colorectal cancer: A new hallmark of oligo-metastatic disease?

  2021cites this paper
• Cross-talk between non-coding RNAs and PI3K/AKT/mTOR pathway in colorectal cancer

  2021cites this paper
• Biological effects and mechanisms of matrine and other constituents of Sophora flavescens in colorectal cancer.

  2021cites this paper
• Anti-Inflammatory Molecular Mechanism and Contribution of Drug Transport Molecules in Colorectal Cancer Cells

  2021cites this paper
• Potential of olive oil and its phenolic compounds as therapeutic intervention against colorectal cancer: a comprehensive review

  2021cites this paper
• The modulation of PI3K/Akt pathway by 3β hydroxylup‐12‐en‐28‐oic acid isolated from Thymus linearis induces cell death in HCT‐116 cells

  2021cites this paper
• The TRIM proteins in cancer: from expression to emerging regulatory mechanisms

  2021cites this paper
• MC1R Is a Prognostic Marker and Its Expression Is Correlated with MSI in Colorectal Cancer

  2021cites this paper
• Harmine Hydrochloride Mediates the Induction of G2/M Cell Cycle Arrest in Breast Cancer Cells by Regulating the MAPKs and AKT/FOXO3a Signaling Pathways

  2021cites this paper
• Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells

  2021cites this paper
• Harmine Hydrochloride Triggers G2/M Cell Cycle Arrest and Apoptosis in HCT116 Cells through ERK and PI3K/AKT/mTOR Signaling Pathways

  2021cites this paper
• Multifaceted Roles of TRIM Proteins in Colorectal Carcinoma

  2020cites this paper
• Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.

  2020cites this paper
• MicroRNAs and Apoptosis in Colorectal Cancer

  2020cites this paper
• IPM712, a vanillin derivative as potential antitumor agents, displays better antitumor activity in colorectal cancers cell lines.

  2020cites this paper
• Oncogenic miRNAs and target therapies in colorectal cancer.

  2020cites this paper
• Analysis and Identification of Active Compounds from Salviae miltiorrhizae Radix Toxic to HCT-116 Human Colon Cancer Cells

  2020cites this paper
• Caffeine and its main targets of colorectal cancer

  2020cites this paper
• Colon cancer-associated transcript-1 enhances glucose metabolism and colon cancer cell activity in a high-glucose environment in vitro and in vivo.

  2020cites this paper
• Target genetic abnormalities for the treatment of colon cancer and its progression to metastasis.

  2020cites this paper
• Stress granules in colorectal cancer: Current knowledge and potential therapeutic applications

  2020cites this paper
• Targeting Pathways in GI Malignancies

  2020cites this paper
• KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: A single-site report

  2020cites this paper
• Identification of Alternatively-Activated Pathways between Primary Breast Cancer and Liver Metastatic Cancer Using Microarray Data

  2019cites this paper
• Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients

  2019cites this paper
• Signaling pathways involved in colorectal cancer progression

  2019cites this paper
• PI3K/ Akt/ mTOR pathway as a therapeutic target for colorectal cancer: A review of preclinical and clinical evidence.

  2019cites this paper
• Mechanism of Apoptosis Induced by Curcumin in Colorectal Cancer

  2019cites this paper
• Role of Regulatory Oncogenic or Tumor Suppressor miRNAs of PI3K/AKT Signaling Axis in the Pathogenesis of Colorectal Cancer.

  2019cites this paper
• Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.

  2019cites this paper
• A Deregulated PI3K-AKT Signaling Pathway in Patients with Colorectal Cancer

  2019cites this paper
• Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer

  2018cites this paper
• Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer.

  2018cites this paper
• Tumour purity as a prognostic factor in colon cancer

  2018cites this paper
• Phosphorylation of p70 Ribosomal Protein S6 Kinase &bgr;‐1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer

  2018cites this paper
• Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway

  2018cites this paper
• Tumour purity as a prognostic factor in colon cancer

  2018cites this paper
• Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer

  2018cites this paper
• Identification of key tumorigenesis‑related genes and their microRNAs in colon cancer.

  2018cites this paper
• Targeted inhibition of the phosphoinositide 3-kinase impairs cell proliferation, survival, and invasion in colon cancer

  2017cites this paper
• Cromolyn chitosan nanoparticles as a novel protective approach for colorectal cancer.

  2017cites this paper
• Perdeuterated and 13C-enriched myo-inositol for DNP assisted monitoring of enzymatic phosphorylation by inositol-3-kinase.

  2017cites this paper
• Targeted inhibition of the phosphoinositide 3-kinase impairs cell proliferation, survival, and invasion in colon cancer

  2017cites this paper